NASDAQ:LUMO
Lumos Pharma Inc. Stock News
$2.80
+0.120 (+4.48%)
At Close: Apr 23, 2024
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
09:00am, Monday, 26'th Feb 2024
AUSTIN, Texas, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th
Lumos Pharma (LUMO) Reports Q3 Loss, Lags Revenue Estimates
09:47pm, Tuesday, 07'th Nov 2023
Lumos Pharma (LUMO) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $1.10. This compares to loss of $0.86 per share a year ago.
Lumos Pharma Announces Participation in Investor Conferences in September
04:34pm, Thursday, 07'th Sep 2023
AUSTIN, Texas, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for moderate Pediatric Growth Hormone Deficiency
Lumos Pharma, Inc. (LUMO) Q2 2023 Earnings Call Transcript
10:27pm, Wednesday, 09'th Aug 2023
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lisa Miller – Senior Director of Investor Relations Rick Hawkins – Chief Executive
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
09:00am, Wednesday, 26'th Jul 2023
AUSTIN, Texas, July 26, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th
Lumos Pharma (LUMO) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Wednesday, 03'rd May 2023
Lumos Pharma (LUMO) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $0.92 per share a year ago.
Lumos Pharma to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023
09:00am, Wednesday, 19'th Apr 2023
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) t
Lumos Pharma (LUMO) Reports Q4 Loss, Tops Revenue Estimates
07:34pm, Wednesday, 01'st Mar 2023
Lumos (LUMO) delivered earnings and revenue surprises of -3.16% and 48.84%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma to Report Full Year 2022 Financial Results and Host Conference Call on March 1, 2023
04:05pm, Wednesday, 15'th Feb 2023
AUSTIN, Texas, Feb. 15, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) th
Lumos Pharma (LUMO) Reports Q3 Loss, Tops Revenue Estimates
09:02am, Monday, 14'th Nov 2022
Lumos (LUMO) delivered earnings and revenue surprises of 14.85% and 24.25%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q2 2022 Results - Earnings Call Transcript
08:36pm, Tuesday, 09'th Aug 2022
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director of Investor Relations Richard Hawkins - Chairman and Chi
Lumos Pharma (LUMO) Reports Q2 Loss, Tops Revenue Estimates
07:33pm, Tuesday, 09'th Aug 2022
Lumos (LUMO) delivered earnings and revenue surprises of 4.08% and 266.36%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Lumos Pharma to Participate in Upcoming Investor Conferences
04:05pm, Monday, 16'th May 2022
AUSTIN, Texas, May 16, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the Company will
Lumos Pharma, Inc. (LUMO) CEO Richard Hawkins on Q1 2022 Results - Earnings Call Transcript
10:03pm, Tuesday, 10'th May 2022
Lumos Pharma, Inc. (NASDAQ:LUMO ) Q1 2022 Earnings Conference Call May 10, 2022 4:30 PM ET Company Participants Lisa Miller - Senior Director, IR Richard Hawkins - CEO & Chairman John McKew - Chief Sc
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call Transcript
10:03pm, Thursday, 10'th Mar 2022
Lumos Pharma, Inc. (LUMO) CEO Rick Hawkins on Q4 2021 Results - Earnings Call Transcript
